Journal of Medicinal Chemistry p. 718 - 738 (2015)
Update date:2022-08-15
Topics:
J?rg, Manuela
May, Lauren T.
Mak, Frankie S.
Lee, Kiew Ching K.
Miller, Neil D.
Scammells, Peter J.
Capuano, Ben
A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and drug-like dual acting molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 241385 as an adenosine A2A receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A2A and dopamine D2). In addition, the integrated dual acting ligands also showed promising results in preliminary blood-brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools.
View MoreContact:86-574-26865651
Address:529 YuanBaoShan Road, Beilun District
Valiant Fine Chemicals Co., Ltd.
Contact:+86 535 6101878/6374484
Address:11 Wuzhishan Rd.,YTETDZ,Yantai,264006,Shandong,China
Jiangsu Zhenfang Chemical CO.,LTD.(Suzhou Zhenfang Chemical Factory)
Contact:+86-512-69598882
Address:Room1201, Jiayuan Road No.1018, Xiangcheng District, Suzhou, China
Qingdao XinYongAn Chemicals Co., Ltd
Contact:+86-532-81107967
Address:Chengyang dual-port industrial park by the sea,Qingdao
Contact:+86-571-28186845
Address:Room 1224,Eastcom Mansion,398 Wensan Road,Hangzhou,310013 China
Doi:10.1021/om00046a012
(1992)Doi:10.1016/j.tetlet.2013.04.064
(2013)Doi:10.1021/om4000538
(2013)Doi:10.3762/bjoc.9.48
(2013)Doi:10.1016/S0040-4039(00)61318-7
(1992)Doi:10.1016/S0040-4039(01)99231-7
(1961)